A global scientific strategy to cure hepatitis B.

[1]  J. Lazarus,et al.  The hepatitis B epidemic and the urgent need for cure preparedness , 2018, Nature Reviews Gastroenterology & Hepatology.

[2]  S. Alavian,et al.  Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. , 2018, The lancet. Gastroenterology & hepatology.

[3]  Lei Yue,et al.  Establishment of Cre‐mediated HBV recombinant cccDNA (rcccDNA) cell line for cccDNA biology and antiviral screening assays , 2018, Antiviral research.

[4]  R. Fleck,et al.  3D microfluidic liver cultures as a physiological preclinical tool for hepatitis B virus infection , 2018, Nature Communications.

[5]  S. Urban,et al.  Hepatitis B Virus DNA Integration Occurs Early in the Viral Life Cycle in an In Vitro Infection Model via Sodium Taurocholate Cotransporting Polypeptide-Dependent Uptake of Enveloped Virus Particles , 2018, Journal of Virology.

[6]  C. Rice,et al.  A research agenda for curing chronic hepatitis B virus infection , 2018, Hepatology.

[7]  N. Haigwood,et al.  Hepatocytic expression of human sodium-taurocholate cotransporting polypeptide enables hepatitis B virus infection of macaques , 2017, Nature Communications.

[8]  C. Rice,et al.  Research priorities for the discovery of a cure for chronic hepatitis B: Report of a workshop , 2017, Antiviral research.

[9]  P. Roingeard,et al.  Viral Load Affects the Immune Response to HBV in Mice With Humanized Immune System and Liver , 2017, Gastroenterology.

[10]  Anh-Hoa Nguyen,et al.  Safety, efficacy and pharmacodynamics of vesatolimod (GS-9620) in virally suppressed patients with chronic hepatitis B. , 2017, Journal of hepatology.

[11]  M. Buti,et al.  The risk of hepatocellular carcinoma decreases after the first 5 years of entecavir or tenofovir in Caucasians with chronic hepatitis B , 2017, Hepatology.

[12]  T. Volz,et al.  Efficacy of NVR 3-778, Alone and In Combination With Pegylated Interferon, vs Entecavir In uPA/SCID Mice With Humanized Livers and HBV Infection. , 2017, Gastroenterology.

[13]  C. Seeger,et al.  Distribution of Hepatitis B Virus Nuclear DNA , 2017, Journal of Virology.

[14]  A. Lok,et al.  Hepatitis B cure: From discovery to regulatory approval , 2017, Hepatology.

[15]  S. Kanner,et al.  RNAi-based treatment of chronically infected patients and chimpanzees reveals that integrated hepatitis B virus DNA is a source of HBsAg , 2017, Science Translational Medicine.

[16]  N. Terrin,et al.  Role of surface antibody in hepatitis B reactivation in patients with resolved infection and hematologic malignancy: A meta‐analysis , 2017, Hepatology.

[17]  Thomas Berg,et al.  EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. , 2017, Journal of hepatology.

[18]  A. Bertoletti,et al.  Lymphocytes transiently expressing virus-specific T cell receptors reduce hepatitis B virus infection , 2017, The Journal of clinical investigation.

[19]  K. Marsh,et al.  Hepatitis B virus infection as a neglected tropical disease , 2017, bioRxiv.

[20]  Leo Swadling,et al.  IL-2high tissue-resident T cells in the human liver: Sentinels for hepatotropic infection , 2017, The Journal of experimental medicine.

[21]  A. Gehring.  New treatments to reach functional cure: Rationale and challenges for emerging immune-based therapies. , 2017, Best practice & research. Clinical gastroenterology.

[22]  M. Dandri,et al.  The Role of cccDNA in HBV Maintenance , 2017, Viruses.

[23]  G. Lauer,et al.  Hepatitis B virus infection and the immune response: The big questions. , 2017, Best practice & research. Clinical gastroenterology.

[24]  A. Lohse,et al.  Proliferation of primary human hepatocytes and prevention of hepatitis B virus reinfection efficiently deplete nuclear cccDNA in vivo , 2017, Gut.

[25]  A. Ely,et al.  Sustained Inhibition of HBV Replication In Vivo after Systemic Injection of AAVs Encoding Artificial Antiviral Primary MicroRNAs , 2017, Molecular therapy. Nucleic acids.

[26]  H. Mizuguchi,et al.  Human induced-pluripotent stem cell-derived hepatocyte-like cells as an in vitro model of human hepatitis B virus infection , 2017, Scientific Reports.

[27]  S. Fletcher,et al.  Identifying and Characterizing Interplay between Hepatitis B Virus X Protein and Smc5/6 , 2017, Viruses.

[28]  Jianming Hu,et al.  Complete and Incomplete Hepatitis B Virus Particles: Formation, Function, and Application , 2017, Viruses.

[29]  T. Liang,et al.  Human stem cell-derived hepatocytes as a model for hepatitis B virus infection, spreading and virus-host interactions. , 2017, Journal of hepatology.

[30]  M. Ferracin,et al.  Targeting mitochondrial dysfunction can restore antiviral activity of exhausted HBV-specific CD8 T cells in chronic hepatitis B , 2017, Nature Medicine.

[31]  T. Volz,et al.  Serum HBV pgRNA as a clinical marker for cccDNA activity. , 2017, Journal of hepatology.

[32]  B. Kallakury,et al.  Antiviral Efficacy and Host Immune Response Induction during Sequential Treatment with SB 9200 Followed by Entecavir in Woodchucks , 2017, PloS one.

[33]  P. Lampertico,et al.  Hepatitis B virus long‐term impact of antiviral therapy nucleot(s)ide analogues (NUCs) , 2017, Liver international : official journal of the International Association for the Study of the Liver.

[34]  T. Hallett,et al.  Requirements for global elimination of hepatitis B: a modelling study. , 2016, The Lancet. Infectious diseases.

[35]  S. Lewin,et al.  Ethics and hepatitis B cure research , 2016, Gut.

[36]  L. Su,et al.  Minicircle HBV cccDNA with a Gaussia luciferase reporter for investigating HBV cccDNA biology and developing cccDNA-targeting drugs , 2016, Scientific Reports.

[37]  Yan Zhou,et al.  HBV DNA Integration and Clonal Hepatocyte Expansion in Chronic Hepatitis B Patients Considered Immune Tolerant. , 2016, Gastroenterology.

[38]  Xiuqing Zhang,et al.  Genomic and oncogenic preference of HBV integration in hepatocellular carcinoma , 2016, Nature Communications.

[39]  N. Xia,et al.  Serum hepatitis B virus RNA is encapsidated pregenome RNA that may be associated with persistence of viral infection and rebound. , 2016, Journal of hepatology.

[40]  Yanbao Yu,et al.  Hepatitis B Virus X Protein Promotes Degradation of SMC5/6 to Enhance HBV Replication. , 2016, Cell reports.

[41]  Reza Assadi,et al.  The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013 , 2016, The Lancet.

[42]  A. Cuconati,et al.  Establishment of an inducible HBV stable cell line that expresses cccDNA-dependent epitope-tagged HBeAg for screening of cccDNA modulators. , 2016, Antiviral research.

[43]  G. Foster,et al.  Interferon Alpha Induces Sustained Changes in NK Cell Responsiveness to Hepatitis B Viral Load Suppression In Vivo , 2016, PLoS pathogens.

[44]  R. D. de Knegt,et al.  Similar frequencies, phenotype and activation status of intrahepatic NK cells in chronic HBV patients after long-term treatment with tenofovir disoproxil fumarate (TDF). , 2016, Antiviral research.

[45]  H. Nakauchi,et al.  Human induced pluripotent stem cell-derived hepatic cell lines as a new model for host interaction with hepatitis B virus , 2016, Scientific Reports.

[46]  E. Thomas,et al.  Experimental models of hepatitis B and C — new insights and progress , 2016, Nature Reviews Gastroenterology &Hepatology.

[47]  F. Zoulim,et al.  HBV cure: why, how, when? , 2016, Current opinion in virology.

[48]  B. Davidson,et al.  CXCR6 marks a novel subset of T-betloEomeshi natural killer cells residing in human liver , 2016, Scientific Reports.

[49]  C. Seeger,et al.  Complete Spectrum of CRISPR/Cas9-induced Mutations on HBV cccDNA , 2016, Molecular therapy : the journal of the American Society of Gene Therapy.

[50]  F. Zoulim,et al.  Global strategies are required to cure and eliminate HBV infection , 2016, Nature Reviews Gastroenterology and Hepatology.

[51]  A. Bertoletti,et al.  Adaptive immunity in HBV infection. , 2016, Journal of hepatology.

[52]  M. Maini,et al.  The role of innate immunity in the immunopathology and treatment of HBV infection. , 2016, Journal of hepatology.

[53]  S. Fletcher,et al.  Hepatitis B virus X protein identifies the Smc5/6 complex as a host restriction factor , 2016, Nature.

[54]  W. Lu,et al.  In situ analysis of intrahepatic virological events in chronic hepatitis B virus infection. , 2016, The Journal of clinical investigation.

[55]  Haitao Guo,et al.  Metabolism and function of hepatitis B virus cccDNA: Implications for the development of cccDNA-targeting antiviral therapeutics. , 2015, Antiviral research.

[56]  A. Boonstra,et al.  Re‐evaluation of hepatitis B virus clinical phases by systems biology identifies unappreciated roles for the innate immune response and B cells , 2015, Hepatology.

[57]  Jianming Hu,et al.  Hepatitis B Virus Covalently Closed Circular DNA Formation in Immortalized Mouse Hepatocytes Associated with Nucleocapsid Destabilization , 2015, Journal of Virology.

[58]  M. Nassal.  HBV cccDNA: viral persistence reservoir and key obstacle for a cure of chronic hepatitis B , 2015, Gut.

[59]  Linda V. Sinclair,et al.  Metabolic regulation of hepatitis B immunopathology by myeloid-derived suppressor cells , 2015, Nature Medicine.

[60]  J. D. Di Santo,et al.  A Novel Mouse Model for Stable Engraftment of a Human Immune System and Human Hepatocytes , 2015, PloS one.

[61]  B. Autran,et al.  Towards an HBV cure: state-of-the-art and unresolved questions—report of the ANRS workshop on HBV cure , 2015, Gut.

[62]  A. Bertoletti,et al.  Immunotherapy of HCC metastases with autologous T cell receptor redirected T cells, targeting HBsAg in a liver transplant patient. , 2015, Journal of hepatology.

[63]  T. Berg,et al.  Serum hepatitis B virus RNA levels as an early predictor of hepatitis B envelope antigen seroconversion during treatment with polymerase inhibitors , 2015, Hepatology.

[64]  R. Thimme,et al.  Restoration of HBV-specific CD8+ T cell function by PD-1 blockade in inactive carrier patients is linked to T cell differentiation. , 2014, Journal of hepatology.

[65]  A. Kramvis.  Genotypes and Genetic Variability of Hepatitis B Virus , 2014, Intervirology.

[66]  R. Gish,et al.  Immunosuppression in Patients with Chronic Hepatitis B , 2014, Current Hepatology Reports.

[67]  F. Chisari,et al.  Comment on “Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA” , 2014, Science.

[68]  M. Heikenwalder,et al.  Response to Comment on “Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA” , 2014, Science.

[69]  P. Knolle,et al.  Hepatic immune regulation and its involvement in viral hepatitis infection. , 2014, Gastroenterology.

[70]  T. Liang,et al.  Specific and Nonhepatotoxic Degradation of Nuclear Hepatitis B Virus cccDNA , 2014, Science.

[71]  J. Kao,et al.  Persistence of hepatitis B virus covalently closed circular DNA in hepatocytes: molecular mechanisms and clinical significance , 2014, Emerging Microbes & Infections.

[72]  Jia Liu,et al.  Enhancing Virus-Specific Immunity In Vivo by Combining Therapeutic Vaccination and PD-L1 Blockade in Chronic Hepadnaviral Infection , 2014, PLoS pathogens.

[73]  M. Aichler,et al.  T cells expressing a chimeric antigen receptor that binds hepatitis B virus envelope proteins control virus replication in mice. , 2013, Gastroenterology.

[74]  Yoshiyuki Suzuki,et al.  Long‐term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection , 2013, Hepatology.

[75]  F. Chisari,et al.  CD40 Activation Rescues Antiviral CD8+ T Cells from PD-1-Mediated Exhaustion , 2013, PLoS pathogens.

[76]  W. Rosenberg,et al.  The Third Signal Cytokine IL-12 Rescues the Anti-Viral Function of Exhausted HBV-Specific CD8 T Cells , 2013, PLoS pathogens.

[77]  M. Maini,et al.  NK Cells: A Double-Edged Sword in Chronic Hepatitis B Virus Infection , 2013, Front. Immunol..

[78]  G. Reynolds,et al.  Up-regulation of a death receptor renders antiviral T cells susceptible to NK cell–mediated deletion , 2013, The Journal of experimental medicine.

[79]  W. Rosenberg,et al.  Upregulation of the Tim-3/Galectin-9 Pathway of T Cell Exhaustion in Chronic Hepatitis B Virus Infection , 2012, PloS one.

[80]  P. Lampertico,et al.  IL-10–Producing Regulatory B Cells in the Pathogenesis of Chronic Hepatitis B Virus Infection , 2012, The Journal of Immunology.

[81]  M. Levrero,et al.  IFN-α inhibits HBV transcription and replication in cell culture and in humanized mice by targeting the epigenetic regulation of the nuclear cccDNA minichromosome. , 2012, The Journal of clinical investigation.

[82]  Fabien Zoulim,et al.  Hepatitis B virus X protein is essential to initiate and maintain virus replication after infection. , 2011, Journal of hepatology.

[83]  G. Hartmann,et al.  5' Triphosphorylated small interfering RNAs control replication of hepatitis B virus and induce an interferon response in human liver cells and mice. , 2011, Gastroenterology.

[84]  A. Bertoletti,et al.  Engineering virus-specific T cells that target HBV infected hepatocytes and hepatocellular carcinoma cell lines. , 2011, Journal of hepatology.

[85]  Ju Zhang,et al.  HBc binds to the CpG islands of HBV cccDNA and promotes an epigenetic permissive state , 2011, Epigenetics.

[86]  M. Maini,et al.  Role of the coinhibitory receptor cytotoxic T lymphocyte antigen‐4 on apoptosis‐Prone CD8 T cells in persistent hepatitis B virus infection , 2011, Hepatology.

[87]  J. Clements,et al.  A simian immunodeficiency virus macaque model of highly active antiretroviral treatment: viral latency in the periphery and the central nervous system , 2011, Current opinion in HIV and AIDS.

[88]  M. Massari,et al.  Antiviral intrahepatic T-cell responses can be restored by blocking programmed death-1 pathway in chronic hepatitis B. , 2010, Gastroenterology.

[89]  M. Levrero,et al.  Nuclear HBx binds the HBV minichromosome and modifies the epigenetic regulation of cccDNA function , 2009, Proceedings of the National Academy of Sciences.

[90]  F. Zoulim,et al.  Hepatitis B virus resistance to nucleos(t)ide analogues. , 2009, Gastroenterology.

[91]  M. Levrero,et al.  Control of cccDNA function in hepatitis B virus infection. , 2009, Journal of hepatology.

[92]  Pratip K. Chattopadhyay,et al.  The Size of the Viral Inoculum Contributes to the Outcome of Hepatitis B Virus Infection , 2009, Journal of Virology.

[93]  I. Hung,et al.  HBsAg Seroclearance in chronic hepatitis B in Asian patients: replicative level and risk of hepatocellular carcinoma. , 2008, Gastroenterology.

[94]  G. Alexander,et al.  Functional skewing of the global CD8 T cell population in chronic hepatitis B virus infection , 2008, The Journal of experimental medicine.

[95]  Chien-Jen Chen,et al.  Long-term outcomes in hepatitis B: the REVEAL-HBV study. , 2007, Clinics in liver disease.

[96]  G. Freeman,et al.  PD-1:PD-L1 Interactions Contribute to the Functional Suppression of Virus-Specific CD8+ T Lymphocytes in the Liver1 , 2007, The Journal of Immunology.

[97]  A. Bertoletti,et al.  Characterization of Hepatitis B Virus (HBV)-Specific T-Cell Dysfunction in Chronic HBV Infection , 2007, Journal of Virology.

[98]  Z. Zou,et al.  Circulating and Liver Resident CD4+CD25+ Regulatory T Cells Actively Influence the Antiviral Immune Response and Disease Progression in Patients with Hepatitis B1 , 2006, The Journal of Immunology.

[99]  M. Levrero,et al.  Hepatitis B virus replication is regulated by the acetylation status of hepatitis B virus cccDNA-bound H3 and H4 histones. , 2006, Gastroenterology.

[100]  Bryan Boyd,et al.  Interferon prevents formation of replication-competent hepatitis B virus RNA-containing nucleocapsids. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[101]  F. Chisari,et al.  Toll-Like Receptor Signaling Inhibits Hepatitis B Virus Replication In Vivo , 2005, Journal of Virology.

[102]  G. Missale,et al.  Acute phase HBV‐specific T cell responses associated with HBV persistence after HBV/HCV coinfection , 2005, Hepatology.

[103]  C. Gibbs,et al.  Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. , 2004, Gastroenterology.

[104]  W. Gerlich,et al.  Pre-S1 Antigen-Dependent Infection of Tupaia Hepatocyte Cultures with Human Hepatitis B Virus , 2003, Journal of Virology.

[105]  B. Rehermann.  Immune Responses in Hepatitis B Virus Infection , 2003, Seminars in liver disease.

[106]  S. Salhi,et al.  Proteolytic Processing of the Hepatitis B Virus e Antigen Precursor , 2003, The Journal of Biological Chemistry.

[107]  R. Purcell,et al.  CD8+ T Cells Mediate Viral Clearance and Disease Pathogenesis during Acute Hepatitis B Virus Infection , 2003, Journal of Virology.

[108]  M. Manns,et al.  Structural organization of the hepatitis B virus minichromosome. , 2001, Journal of molecular biology.

[109]  M. Shapiro,et al.  Viral clearance without destruction of infected cells during acute HBV infection. , 1999, Science.

[110]  C. Rice,et al.  Differential cytotoxic T-lymphocyte responsiveness to the hepatitis B and C viruses in chronically infected patients , 1996, Journal of virology.

[111]  F. Chisari,et al.  The hepatitis B virus persists for decades after patients' recovery from acute viral hepatitis despite active maintenance of a cytotoxic T–lymphocyte response , 1996, Nature Medicine.

[112]  H. Blum,et al.  Hepatitis B virus infection of tupaia hepatocytes in vitro and in vivo , 1996, Hepatology.

[113]  S. Locarnini,et al.  The covalently closed duplex form of the hepadnavirus genome exists in situ as a heterogeneous population of viral minichromosomes , 1995, Journal of virology.

[114]  H. Alter,et al.  A "NEW" ANTIGEN IN LEUKEMIA SERA. , 1965, JAMA.

[115]  A. Ely,et al.  A T7 Endonuclease I Assay to Detect Talen-Mediated Targeted Mutation of HBV cccDNA. , 2017, Methods in molecular biology.

[116]  M. Heikenwalder,et al.  Interferon-γ and Tumor Necrosis Factor-α Produced by T Cells Reduce the HBV Persistence Form, cccDNA, Without Cytolysis. , 2016, Gastroenterology.

[117]  Y. Falck‐Ytter,et al.  American Gastroenterological Association Institute Technical Review on Prevention and Treatment of Hepatitis B Reactivation During Immunosuppressive Drug Therapy , 2014 .

[118]  D. Campana,et al.  A Practical Approach to Immunotherapy of Hepatocellular Carcinoma Using T Cells Redirected Against Hepatitis B Virus. , 2013, Molecular therapy. Nucleic acids.

[119]  Wenhui Li,et al.  Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus. , 2012, eLife.

[120]  S. Urban,et al.  T cells redirected against hepatitis B virus surface proteins eliminate infected hepatocytes. , 2008, Gastroenterology.

[121]  G. Freeman,et al.  PD-1:PD-L1 Interactions Contribute to the Functional Suppression of Virus-Specific CD8 T Lymphocytes in the Liver , 2007 .

[122]  F. Chisari,et al.  Hepatitis B virus immunopathogenesis. , 1995, Annual review of immunology.

[123]  F. Chisari,et al.  Hepatitis B virus persistence after recovery from acute viral hepatitis. , 1994, The Journal of clinical investigation.